Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jan 2026 According to FibroGen media release, FibroGen is now called as Kyntra Bio.
18 May 2022 Results from four pivotal trials (ASCEND-NHQ , ALPS, ANDES, OLYMPUS) assessing indirect treatment comparison (ITC) of changes in SF-36 Vitality score observed in placebo-controlled RCTs of daprodustat and roxadustat presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
14 Dec 2021 Results of pooled post-hoc analysis assessing the effects of roxadustat in patients (pts) with NDD-CKD across all available BL Hb values from three Phase 3 NDD-CKD trials (OLYMPUS, ALPS, ANDES) presented at the 63rd American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com